LBIO (Longevity Biomedical) Construction In Progress: $0.00 Mil (As of . 20)


What is Longevity Biomedical Construction In Progress?

Longevity Biomedical LBIO Construction In Progress is $0.00 Mil as of . 20.

Longevity Biomedical Construction In Progress Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Construction In Progress Chart

Longevity Biomedical Annual Data
Trend
Construction In Progress

Longevity Biomedical Semi-Annual Data
Construction In Progress

Longevity Biomedical Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Longevity Biomedical (LBIO) has a Construction In Progress of $0.00 Mil as of . 20. Construction in Progress records the amount of construction work that is not complete. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's Construction In Progress too high?
Longevity Biomedical's current Construction In Progress is $0.00 Mil.
How does Longevity Biomedical's Construction In Progress compare to ?
Longevity Biomedical's Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Construction In Progress of $0.00 Mil. The current Construction In Progress is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Construction In Progress is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.